Skip to main content

Advertisement

Table 2 Circulating concentrations of osteoprotegerin and breast cancer risk by hormone-receptor subtype: EPIC cohort breast cancer nested case-control study

From: Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort

  Tertiles    
1 2 3    
Cut points (ng/mL) <0.18 0.18 - <0.22 ≥0.22 p trend a RRlog2 b p het c
ER+/PR+
 Cases/controls 342/312 297/308 290/309    
 RR (95% CI) Ref. 0.84 (0.65-1.07) 0.81 (0.61-1.08) 0.27 0.85 (0.63-1.14) 0.02
ER+
 Cases/controls 559/510 519/544 544/568    
 RR (95% CI) Ref. 0.84 (0.70-1.02) 0.84 (0.68-1.04) 0.18 0.86 (0.68-1.08) 0.02
ER–/PR–
 Cases/controls 82/96 78/96 98/66    
 RR (95% CI) Ref. 1.12 (0.68-1.83) 2.39 (1.35-4.23) 0.04 1.89 (1.03-3.47)  
ER–
 Cases/controls 139/160 117/125 130/101    
 RR (95% CI) Ref. 1.22 (0.83-1.83) 1.93 (1.24-3.02) 0.03 1.69 (1.05-2.74)  
  1. Conditional logistic regression models adjusted for ages at menarche (≤12, 13, 14, ≥15, missing), menopause (<44, 44-47, 48-50, 51-52, 53-54, ≥55, missing), first full-term pregnancy (no FTP, <25, 25-30, ≥30, missing), number of full-term pregnancies (0, 1, 2, ≥3, missing), and BMI (kg/m2, continuous)
  2. a p trend based on log2-transformed OPG concentration
  3. bRR for a one-unit change in log2-transformed OPG
  4. c p heterogeneity comparing ER+/PR+ to ER–/PR– and ER+ to ER– subtypes, based on log2-transformed OPG concentration